BridgeBio Oncology Therapeutics, Inc. (BBOT)
| Market Cap | 843.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -87.50M |
| Shares Out | 86.45M |
| EPS (ttm) | -268.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,101 |
| Open | 9.60 |
| Previous Close | 9.58 |
| Day's Range | 9.43 - 9.99 |
| 52-Week Range | 8.70 - 12.50 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 25.00 (+156.15%) |
| Earnings Date | n/a |
About BBOT
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients. The company is based in South San Francisco, California. BridgeBio Oncology Therapeutics, Inc. operates as a subsidiary of BridgeBio Pharma, Inc. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for BBOT stock is "Buy" and the 12-month stock price target is $25.0.
News
BBOT to Participate in Upcoming September Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025. Closed conc...